Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
765 participants
OBSERVATIONAL
2022-09-15
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preoperative Estimation of Microvascular Invasion in Hepatocellular Carcinoma
NCT03110068
The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma
NCT02525965
Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer
NCT01034865
Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies
NCT05613621
Comprehensive Prognostic Model: The Study Introduces a Novel Prognostic Model That Incorporates a Wide Range of Clinical and Laboratory Variables, Providing a More Holistic Approach to Predicting Overall Survival in HCC Patients
NCT06550739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
training cohort
HCC patients receiving curative hepatic resection
observing whether HCC patients having tumor micronecrosis
whether HCC patients having tumor micronecrosis or not
validation cohort
HCC patients receiving curative hepatic resection
observing whether HCC patients having tumor micronecrosis
whether HCC patients having tumor micronecrosis or not
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
observing whether HCC patients having tumor micronecrosis
whether HCC patients having tumor micronecrosis or not
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. curative hepatectomy with R0 resection;
3. conserved liver function with Child Pugh class A or B
Exclusion Criteria
2. receiving other anti-tumor treatments such as TACE or systemic drugs;
3. with other primary cancers;
4. incomplete follow-up data;
5. without sufficient formalin-fixed, paraffin-embedded (FFPE) specimens for micronecrosis evaluation
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
TingBo Liang
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMforHCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.